Toward a prostate cancer precision medicine - Abstract

The promise of precision cancer medicine is that we will be able to pair clinical and genomic data to provide better and more efficient treatment for cancer care.

Although the focus is on the optimal pairing of existing Food and Drug Administration-approved drugs with the patient׳s tumor, precision medicine should also help determine a patient׳s risk for disease progression. Precision medicine will hopefully also lead to improved molecular biomarkers. The specific needs for predictive biomarkers vary significantly based on cancer type. The chief aim for prostate cancer biomarker development is to help distinguish indolent from aggressive disease.

Written by:
Rubin MA.   Are you the author?
Institute for Precision Medicine of Weill Cornell Medical College and NewYork-Presbyterian Hospital, New York, NY; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY; Department of Urology, Weill Cornell Medical College, New York, NY; Meyer Cancer Center of Weill Cornell Medical College and NewYork-Presbyterian Hospital, New York, NY.  

Reference: Urol Oncol. 2014 Nov 20. pii: S1078-1439(14)00354-8.
doi: 10.1016/j.urolonc.2014.10.011


PubMed Abstract
PMID: 25465299

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe